pipeline

Novo Nordisk
Biotech

Novo drops oncology ambitions, early-stage MASH prospects

The Danish pharma is winding down a range of early-stage programs for liver disease, oncology and stem cells.
James Waldron Nov 5, 2025 7:21am
Amgen

Amgen halts gastric cancer trial after subpar efficacy analysis

Nov 5, 2025 4:35am
Graphic image of a red thumbs down against a blue background

FDA rejects Biohaven approval request, triggering cost cutting

Nov 5, 2025 4:02am
cartoon of man unplugging from outlet

Pfizer pulls the plug on 11 programs

Nov 4, 2025 2:40pm
Red light traffic

Harmony halts genetic disease program after phase 3 failure

Nov 4, 2025 12:45pm
yellow light street light traffic pause slow delay

Tempero pauses alcohol disorder work, mulls options: Nxera

Nov 3, 2025 9:45am